Brazil hones reg focus of medtech competitiveness drive
This article was originally published in Clinica
Brazilian regulatory agency Anvisa has launched an initiative to "promote and strengthen" domestic production and market entry of medical technology, with an emphasis on the needs of the high proportion of micro-sized and small manufacturers.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.